SYK and COVID-19: Fostamatinib’s inhibition of SYK plays a crucial role in reducing pro-inflammatory cytokine release, neutrophil extracellular trap production, and platelet aggregation, offering potential relief from organ dysfunction in critically ill COVID-19 patients (51, 85–88).